SPARC and GluA1-Containing AMPA Receptors Promote Neuronal Health Following CNS Injury
Authors:
Open Access
- 1 February 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 12, 22
Abstract
The proper formation and maintenance of functional synapses in the central nervous system (CNS) requires communication between neurons and astrocytes and the ability of astrocytes to release neuromodulatory molecules. Previously, we described a novel role for the astrocyte-secreted matricellular protein SPARC (Secreted Protein, Acidic and Rich in Cysteine) in regulating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) and plasticity at developing synapses. SPARC is highly expressed by astrocytes and microglia during CNS development but its level is reduced in adulthood. Interestingly, SPARC has been shown to be upregulated in CNS injury and disease. However, the role of SPARC upregulation in these contexts is not fully understood. In this study, we investigated the effect of chronic SPARC administration on glutamate receptors on mature hippocampal neuron cultures and following CNS injury. We found that SPARC treatment increased the number of GluA1-containing AMPARs at synapses and enhanced synaptic function. Furthermore, we determined that the increase in synaptic strength induced by SPARC could be inhibited by Philanthotoxin-433, a blocker of homomeric GluA1-containing AMPARs. We then investigated the effect of SPARC treatment on neuronal health in an injury context where SPARC expression is upregulated. We found that SPARC levels are increased in astrocytes and microglia following middle cerebral artery occlusion (MCAO) in vivo and oxygen-glucose deprivation (OGD) in vitro. Remarkably, chronic pre-treatment with SPARC prevented OGD-induced loss of synaptic GluA1. Furthermore, SPARC treatment reduced neuronal death through Philanthotoxin-433 sensitive GluA1 receptors. Taken together, this study suggests a novel role for SPARC and GluA1 in promoting neuronal health and recovery following CNS damage.Keywords
Funding Information
- Canadian Institutes of Health Research (MOP 111152/MOP 123390)
- Natural Sciences and Engineering Research Council of Canada (408044-2011)
- Canada Excellence Research Chairs, Government of Canada
- Fondation Brain Canada
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PA00A3-121419)
- FP7 People: Marie-Curie Actions (254022)
This publication has 79 references indexed in Scilit:
- RanBP9 aggravates synaptic damage in the mouse brain and is inversely correlated to spinophilin levels in Alzheimer’s brain synaptosomesCell Death & Disease, 2013
- Proteomic Analysis of α-Amino-3-hydroxy-5-methyl-4-isoxazole Propionate Receptor ComplexesJournal of Biological Chemistry, 2012
- Control of excitatory CNS synaptogenesis by astrocyte-secreted proteins Hevin and SPARCProceedings of the National Academy of Sciences of the United States of America, 2011
- Astrocytes: biology and pathologyActa Neuropathologica, 2009
- Molecular dissection of reactive astrogliosis and glial scar formationTrends in Neurosciences, 2009
- The role of astrocyte-secreted matricellular proteins in central nervous system development and functionJournal of Cell Communication and Signaling, 2009
- PICK1-mediated Glutamate Receptor Subunit 2 (GluR2) Trafficking Contributes to Cell Death in Oxygen/Glucose-deprived Hippocampal NeuronsJournal of Biological Chemistry, 2009
- Subunit Composition of Synaptic AMPA Receptors Revealed by a Single-Cell Genetic ApproachNeuron, 2009
- AMPA glutamate receptor subunits 1 and 2 regulate dendrite complexity and spine motility in neurons of the developing neocortexNeuroscience, 2009
- AMPA receptors regulate experience-dependent dendritic arbor growth in vivoProceedings of the National Academy of Sciences, 2006